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The International AIDS Society convened the multi-stakeholder “Towards an HIV Cure” symposium in Kuala Lumpur,
Malaysia in 2013 to address the significant research challenges posed by the search for a cure for HIV infection.
Current antiretroviral regimens select for a small reservoir of cells that harbour latent HIV provirus, produce few or
no HIV virions, and resist detection or clearance by host immunity. The symposium examined basic molecular sci-
ence and animal model data, and emerging and ongoing clinical trial results to prioritise strategies and determine
the viral and immune responses that could lead to HIV remission without ART. Here we review the presentations
that scrutinized the molecular mechanisms controlling virus expression from proviral DNA, and the intrinsic cellular
restriction and immune mechanisms preventing viral production. Insights from the basic science have translated
into new therapeutic strategies seeking HIV remission without ongoing therapy, and much interest was focused on
these ongoing trials. We also summarise the emerging ethical issues and patient expectations as concepts move
into the clinic.Introduction
The International AIDS Society (IAS) meetings over the
past 25 years have been a focal point for optimising
strategies to tackle the HIV epidemic. Antiretroviral
therapy (ART) has dramatically improved HIV-associ-
ated morbidity and mortality, but is not a cure. Under
the leadership of Françoise Barré-Sinoussi, co-discoverer
of HIV, the IAS is focussing on achieving a safe, afford-
able and scalable cure for HIV infection [1].
There have been a number of high profile case reports
of apparent HIV cure. The well-publicised “Berlin pa-
tient” was treated for acute myeloid leukemia with inten-
sive conditioning to deplete his haematopoietic system
ahead of restorative transplantation with homozygous
CCR5Δ32 bone marrow stem cells, and subsequently be-
came aviraemic [2,3]. More recently, the cases of the
“Mississippi baby” [4] and adults in the French VIS-
CONTI cohort provide potential insights into the impact
of ART when given very early in infection. Together the
experiences of these individuals suggest that a cure is
feasible, not withstanding the inherent challenge of* Correspondence: dfjp@unimelb.edu.au
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reproduction in any medium, provided the oreliminating every potentially replication competent pro-
virus from the body [5].
The IAS “Towards an HIV Cure” annual symposium
brings together basic scientists, clinicians, funders, and
community advocates to address the key challenges
facing the community in bringing about a cure for HIV.
In this review, we summarise the key findings from the
2013 symposium, held in Kuala Lumpur, Malaysia on
29 and 30 June. Initially focusing on the basic science
underpinning the reservoir, HIV transcription control
and immune responses, the report then focuses on clin-
ical trial and ex vivo data, before summarising the key
ethical and regulatory issues.
Molecular mechanisms restricting gene expression from
HIV provirus
Investigations of non-productive HIV infection in reser-
voir cells have yielded important insights into molecular
factors governing HIV latency [6,7]. Olivier Rohr from
the University of Strasbourg presented new data on the
cellular transcription factor CTIP2 from microglial cells
that repress HIV through a range of interconnected
activities [8]. CTIP2 binds to SP1 sites in the HIV core
promoter and recruits histone deacetylases (HDACs)
and the H3K9 methyltransferase, SUV39H1, resulting
in repressive heterochromatin structure at the firstLtd. This is an open access article distributed under the terms of the Creative
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gises with LSD1, normally a lysine specific demethylase,
to instead tri-methylate histone H3K4 and H3K9 at the
HIV promoter, strongly repressing HIV LTR transcrip-
tional activity. CTIP2 also associates with p-TEFb, nor-
mally a potent Tat-responsive transcription elongation
factor. Intriguingly CTIP2 recruits pTEF-b into an in-
active complex repressing expression from the HIV pro-
moter. CTIP2 synergises with another repressive factor,
HMGA1, in silencing HIV gene transcription. Further-
more CTIP2 serves to anchor an inactive form of
p-TEFb to nascent HIV TAR RNA, and inhibits the
transcription trans-activation activity of Tat. While
CTIP2 may not participate in HIV repression in T-cells,
it is an important HIV repressive pathway in cells of the
myeloid lineage that opens new opportunities for thera-
peutic intervention. It is potentially beneficial that over-
lapping cellular functions also controlled by the CTIP2/
p-TEFb repressive complex include many genes that par-
ticipate in the response to HIV.
Several presentations detailed in vitro analyses of
chemotherapeutic approaches targeting expression from
the latent HIV provirus promoter. Most of these
studies compared effects with the pan-HDAC inhibitor
(HDACi), vorinostat (SAHA) that targets all four classes
of HDAC and has been shown to activate virus tran-
scription in resting CD4+ T-cells in HIV-infected pa-
tients on ART in two clinical studies lead by David
Margolis [9] and Sharon Lewin (Elliott CROI 2013). Dr.
Wightman from the latter group presented an evaluation
of newer HDACi’s using a primary T-cell and cell line
models of latency for more potent, less toxic and more
selective compounds [10]. While all the tested HDACi
activated HIV production in latently infected primary T-
cells, entinostat and vorinostat had greatest potency and
panobinostat, another pan-HDACi, had greatest toxicity.
Molecular studies confirmed that entinostat achieved su-
perior viral activation while acting on only HDAC1
among the four HDAC classes in the primary cell model
of latency, promising fewer adverse activities. While
these studies did not examine effects of these alternative
HDACi on latently infected cells from patients, it was
reassuring that there were no effects on markers of im-
mune function and identified entinostat, an Ames-test
negative HDACi, as a strong future candidate for clinical
trial for HIV activation.
Dr. Mahmoudi from Erasmus Medical College, Rotter-
dam explored how the Wnt pathway promotes an accu-
mulation of β-catenin, which in turn evicts repressors
from TCF/LEF-1 sites, as found in the HIV LTR pro-
moter to promote transcription [11]. Treatment of cell
line and primary T-cell models of HIV latency with nat-
ural ligands of Wnt receptors, Wnt3A and R-spondin,
promoted recruitment of TCF/LEF and β-catenin to theLTR and activated latent HIV. Wnt-mediated activation
of latent HIV was synergistically augmented with lithium
chloride that blocks GSK3β-mediated ubiquitylation and
degradation of β-catenin [12], and with the HDACi
SAHA.
Mathias Lichterfeld presented data on memory stem
cells (TSCM), a recently described T cell subset with a
naïve-like phenotype, but functional memory character-
istics. Although the overall contribution to the CD4 T
cell reservoir was low compared with central or effector
memory cells, the proportion of TSCM’s infected was
higher (although not significantly) and less impacted by
ART. Inhibition of the Wnt/ β-catenin pathway - which
has been associated with TSCM induction – was used to
test impact on the HIV-1 reservoir. The agent PRI-724/
C82 (a β-catenin inhibitor) was shown to induce differ-
entiation of TSCM into shorter-lived subsets ex vivo, sug-
gesting a possible role in cure strategies. Preliminary
data showed synergy between Panobinostat and PRI-
724/C82 for both acetylation and intracellular HIV-1
RNA expression in the HIV latently infected ACH-2 cell
line. Taken together, the studies on Wnt/ β-catenin path-
way highlight opportunities for developing more effect-
ive drug cocktails to activate latent HIV and reduce the
lifespan of the TSCM reservoir. However, potential prob-
lems from the strong association of Wnt pathway activa-
tion with solid tumour malignancies and other broad
cellular activities need to be addressed.
Intrinsic and adaptive immune control of latent HIV
infection
Cellular interactions between T-lymphocytes and HIV
infected dendritic cells (DC) are known to promote effi-
cient HIV-1 transmission [13]. Bin Su from the Univer-
sity of Strasbourg, France, showed data that indicates
this crosstalk also stimulates HIV-1 replication in DCs
by inducing reduced expression of the host restriction
factor SAMHD1 that hydrolyses dNTPs to low levels in
monocyte derived DCs (mDC). Direct cell-cell contact
induces a reduction in DC SAMHD1 to similar low
levels as occur following Vpx antagonism during SIV or
HIV-2 infection. Therefore, mDC interactions with CD4
T or B cells promote sufficient dNTP levels to support
HIV-1 replication. These findings were confirmed and
extended by Dr. Xu Yu from the Ragon Institute in
Boston, USA, who compared HIV replication and the
relative strength of the intrinsic immune responses in
mDCs from elite controller patients who have low HIV
loads without ART, with chronic progressing and HIV
naïve individuals. Stronger cell intrinsic IFN-I responses
were observed in mDC from elite controllers (EC) and
this was associated with the accumulation of viral RT
products and diminished proviral integration. A
proposed mechanism was that EC patients expressed
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strict RT and lower levels of LEDGF/p75 and Transpor-
tin 3 that promote integration. It was proposed that
accumulating viral intermediates drive elevated type-I
IFN production by infected mDCs, and consequently en-
hanced CD4 and CD8 T-cell responses. Drugs developed
to target this DC-lymphocyte crosstalk and the intrinsic
sensing of viral products by DCs may interfere with
HIV-1 replication in DCs and enhance more highly-
effective IFN-stimulated cellular immune responses.
A study from Dr. Ndhlovu from University of Hawaii
examined a β-galactoside binding lectin, Galectin-9
(Gal-9), that was proposed to contribute to persistent T-
cell activation and HIV entry into resting cells, but also
to induce CD4 T cell apoptosis and immunosuppression
after binding the Tim-3 receptor [14,15]. Plasma from
EC had elevated levels of Gal-9, and CD8+ T-cells
had elevated Tim-3 receptor levels compared to ART-
suppressed patients, and both were higher than in unin-
fected patients. Recombinant Gal-9 selectively killed
CD8 cells and drove CD4 T-cell responses and this was
blocked with α-lactose as a competitive inhibitor, sug-
gesting a testable new therapeutic intervention.
Characterising the latent HIV reservoir
Sarah Palmer presented longitudinal analyses of single
genome sequences exploring the dynamics of the HIV
reservoir during suppressive therapy. Patients recruited
in both acute and chronic infection and on ART for be-
tween 4 to 12 years were sampled from compartments
including peripheral blood, bone marrow, gut associated
lymphoid tissue and lymph node. Patients were sampled
prior to ART and then twice (6 months apart) after sup-
pressive therapy. Dr Palmer reported a substantially
higher frequency of infection in patients treated in
chronic versus acute infection in all T cell subsets from
both blood and GALT. Interestingly, the central/transi-
tional memory cell compartment contained the majority
of the reservoir in the peripheral blood (mean 56.3%),
whereas in the GALT most infected cells were in the ef-
fector memory compartment (mean 68.4%). Phylogenetic
analyses based on a Gag-Pol fragment provided no evi-
dence for on-going viral replication during the years of
suppressive therapy in any compartment.
Richard Koup presented an analysis of spliced and
unspliced HIV RNA in CD4 T cells sorted into bright,
dim and null cells. Cells containing single copies of
spliced and unspliced RNA transcripts were identified by
qPCR, with spliced tat and rev transcripts used to
discriminate active viral RNA production from the gen-
omic RNA present in incoming virions. Full-length HIV
RNA transcription was associated with CD4 down-
regulation, and the greatest numbers of HIV RNA tran-
scripts were found predominantly in activated cells.Labeled monoclonal antibodies against Env were used to
sort HIV infected cells. However, although monoclonal
antibodies could be used to identify infected T cells in
an in vitro model (particularly anti-V1V2, VRC07 and
PGT121 antibodies), the signal from ex vivo index sorted
samples was weak making the detection of HIV Env ex-
pression using mAbs difficult in these samples.
Clinical studies exploring the role of ART in HIV cure
strategies
Treating early in paediatric HIV infection
Deborah Persaud gave a keynote presentation on the im-
pact of ART on the HIV-1 reservoir in the paediatric set-
ting. She defined ‘cure’ in children as permanent disease
remission off ART, with normal CD4 counts, preserva-
tion of immunity to childhood vaccinations and no evi-
dence for immune activation or inflammation. The case
of the Mississippi child first reported at the Conference
on Retroviruses and Opportunistic Infections (CROI)
2013 was reviewed, with confirmation that the child –
now 33 months old – remains in remission with no viro-
logical or immunological evidence of HIV-associated
pathogenesis [4]. Perinatal infection provides a unique
opportunity to determine how early cART might impact
reservoirs in neonates when the majority of blood T
lymphocytes are a naïve CD45RA phenotype, and pos-
sibly less prone to infection [16,17].
Whereas it is clear that HIV-related mortality is high
in untreated children (36.8% at one year), early ART
started within 3 months saves lives, based on data from
the CHER Trial [18], but although early ART restricts
the reservoir size, it remains detectable in 60% of cases
treated at 2 months [19]. Additionally, early suppressive
ART limited viral diversity and resulted in clearance of
HIV-1 specific antibodies. In a comparison of children
treated early (n = 5) versus late (n = 4), the former had
significantly lower reservoirs (using both proviral load
quantification (p = 0.048) and IUPM assays (p = 0.008)).
After a median of 187 months of ART no replication
competent virus could be recovered from the early-
treated children in contrast to those treated late (4/4 de-
tectable). The data indicated that treatment in the first
few weeks of life made a significant difference compared
to those treated after 3 months. However, models of pro-
viral decay suggested that it could take around 20 years
for the proviral load to become undetectable in those
treated early.
The impact of ART in early and chronic adult HIV infection
Laurent Hocqueloux presented data on the timing of
ART initiation in chronically infected adults [20,21]. In
an analysis of 309 patients with sustained virological
suppression followed for a median of 3.7 years, the pro-
portion of patients achieving a composite endpoint of a
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HIV DNA <2.3 log copy/106 PBMC, after initiating ART
in the < 200, 200 – 499, ≥ 500 CD4 count strata were 0%
(n = 124), 3% (n = 155) and 30% (n = 30), respectively, re-
inforcing the importance of the nadir CD4 cell count. In
contrast, an analysis of treatment commenced in
primary HIV infection (PHI) was presented by Antoine
Chéret from the ANRS 147 OPTIPRIM study - a ran-
domized study of tenofovir/emtricitabine and ritonavir-
boosted darunavir with or without raltegravir and
maraviroc [22,23]. Data from both study arms showed a
reduction in HIV DNA of a median −1.34 log copies/106
PBMC between baseline and 12 months in 67 patients.
This reduction negatively correlated with baseline
plasma HIV RNA and HIV DNA. In the SPARTAC trial
a delay in viral rebound had been reported following
treatment with a 48-week course of ART in primary
HIV infection [24]. James Williams from the University
of Oxford presented cross-sectional and longitudinal
data from SPARTAC showing a significant decrease in
the reservoir after 12 weeks of ART, and with evidence
of rapid rebound on stopping therapy. Correlations were
shown between both ‘total’ and ‘integrated’ proviral load
measurements at the point of stopping ART (p = 0.017
and p = 0.041, respectively) and the time to the trial pri-
mary end-point (of reaching a CD4 cell count of 350
cells/ul or commencing long term ART), confirming the
clinical relevance of proviral quantification. Together
these studies reinforce the key opportunity that PHI rep-
resents for restricting the size of the HIV reservoir with
early ART. A key question is whether the rate of proviral
decay differs in those treated early versus late, once virus
is controlled.
Clinical studies to activate latent HIV gene expression
Preliminary findings from the CLEAR trial were pre-
sented by Dr. Tolstrup from Aarhus University,
Denmark. This was a single arm study of panobinostat, a
pan-HDAC inhibitor, given as a 20 mg oral dose three
times a week, every other week over 8 weeks, to 15
adults on suppressive ART with a CD4 count > 500
cells/mm3. Data for the primary endpoint of cell-
associated HIV RNA were not available, but a qualitative
transcription mediated amplification (TMA) system
(PROCLEIX ULTRIO Plus, Genprobe) was presented
showing that the proportion of samples which were
positive increased from 26% pre-treatment to 60% dur-
ing the first treatment week (p = 0.009). These may rep-
resent the first data of an activating agent leading to
plasma release of viral particles, although a more com-
prehensive analysis is needed. In addition, there was
clear evidence of rapid acetylation/deacetylation with
each cycle of treatment and good tolerability, with no
adverse events greater than grade I, and no significantdifferences in neutrophil or platelet counts. An optional
analytical treatment interruption is planned for all
participants.
IL-7 induces HIV production in vitro from resting
CD4 T cell subsets [25]. The ERAMUNE 01 study was
an international, randomized study of 56 weeks of in-
tensification with raltegravir and maraviroc with or with-
out three doses of IL-7 in adults on suppressive ART
with CD4 count ≥ 350 cells/mm3 and proviral HIV DNA
between 10 and 1000 copies/106 PBMC. Twenty-nine
participants were randomized and all have completed
80 weeks of follow up. Baseline characteristics were well
matched apart from longer duration of ART (median 13
versus 7 years) and higher median baseline HIV DNA
(564 versus 287 copies/106 PBMC) in the IL-7 arm. No
participant reached the primary endpoint of at least a
0.5 log decrease in proviral HIV DNA in PBMC at
56 weeks. A large increase in CD4+ and CD8+ cells in
blood was seen in the IL-7 arm at week 12, which de-
clined thereafter, but remained significantly higher than
baseline at week 56. Most of this increase was in central
memory T-cells (TCM). No significant change in HIV
DNA concentration was seen at 56 or 80 weeks in either
arm when analysed as copies per 106 PBMC or per 106
CD4 cells, but a significant increase was seen at both
time points in the IL-7 arm when analysed as copies per
mL of whole blood, due to persistence of the CD4 cell
count increase. A trend was seen towards lower HIV
DNA in the intensification only arm at week 80
(P = 0.064), but not at earlier time points. The increase
in the HIV reservoir in the IL-7 arm would seem to pre-
clude the use of this agent to purge the HIV reservoir.
Bone marrow transplantation to eliminate the HIV
reservoir
Timothy Henrich presented data from two HIV + ve in-
dividuals who had received allogeneic stem cell trans-
plants and had subsequently undertaken a treatment
interruption. Both recipients were CCR5Δ32 heterozy-
gotes, underwent reduced-intensity conditioning ahead
of allogeneic hematopoietic stem cell transplantation
from wild type (WT) CCR5 donors and both had signifi-
cant chronic graft-versus-host disease [26]. Prior to
treatment interruption at 4.3 and 2.6 years post-
transplant, there was no evidence of HIV infection with
negative HIV DNA and viral outgrowth assays. Micro-
chimerism assays demonstrated that donor cells consti-
tuted virtually 100% of PBMCs, but the mechanisms
driving this were not clear. Both patients were being
followed with weekly plasma HIV RNA and biweekly
PBMC HIV DNA testing, as well as regular single copy
HIV RNA assays and large volume PBMC sampling. At
weeks 7 and 14 post-interruption, no HIV plasma RNA
or PBMC DNA had been detected, and although longer
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early evidence for two further cures. The contrast with
the ‘Berlin’ patient who received the CCR5Δ32 trans-
plant is striking, and raises the intriguing possibility that
the graft versus host response rather then the HIV re-
sistance of the transplanted cells that was the key deter-
minant of viral clearance.
Immunological interventions to target latent HIV infection
Clinical trials testing therapeutic strategies to reactivate
latent virus have highlighted the need to concurrently
boost immune responses to clear cells expressing anti-
gens from reawakened provirus. The role of dendritic
cells (DC) in enhancing this response received attention
in three presentations. Kellie Smith from the University
of Pittsburgh developed a DC immunotherapy using au-
tologous DC loaded with inactivated HIV-1 derived from
the autologous ART reservoir to efficiently prime re-
sidual memory T-cells and naïve CD8+ T cells that
jointly kill HIV superinfected CD4+ T-cells. These data
demonstrated that chronic, untreated HIV-1 infection
did not irreparably damage the ability to prime CTL
against autologous virus with DC expressing antigens
specific for the autologous HIV-1 reservoir, reinforcing
the potential for DC-based immunotherapies.
Eric Arts showed that efficient yeast cloning and re-
combination techniques [27] could be used to prepare
replication-incompetent lentivectors expressing autolo-
gous viral antigens from plasma taken at the commence-
ment of ART. These vectors were used to present
autologous viral antigens on DCs, leading to high-level
stimulation of HIV production from lately infected
CD4+ T-cells compared to reference strain HIV or other
common antigens. This activating vector may also serve
as a useful therapeutic vaccine stimulating CTL to clear
reactivating HIV, and clinical trials are advancing to test
this concept.
An alternative approach developed by Argos Thera-
peutics uses electroporation to introduce Gag, Nef, Rev
and Vpr RNA from autologous HIV into DC, together
with RNA expressing CD40L to enhance antigen-specific
immune stimulation without CD4+ T-cell help as an im-
munotherapy concept called AGS-004. Initial clinical
studies examining six monthly dosing of AGS-004 gave
promising results in reducing viral set point by 1.2 logs
and reducing proviral load in some patients.
Una O’Doherty from the University of Pennsylvania
presented data using a primary CD4 T cell model of la-
tency in which she has previously reported Gag protein
expression [28]. CD4 T cells from elite suppressors were
superinfected and targeted with autologous CD8 cells.
Killing was evidenced by a drop in Gag + ve ‘latent’ cells
from 10.3% to 4.4%, which could be blocked with an
anti-MHC antibody. In an in vivo application of themodel, only between 0.1 and 2% of latently infected cells
were found to produce Gag, which might be of concern
if immunotherapy is to be an integral part of HIV cure.
Dr. Shuzo Matsushita presented data from KD-1002, a
phase 1b dose escalation study of KD-247, a neutralizing
humanized monoclonal antibody [29,30]. Twenty-seven
HIV + ve adults were enrolled off ART, with a CD4
count >350 cells/mm3 and a HIV envelope gene se-
quence encoding the principal neutralizing determinant
(V3-tip) corresponding to high KD-247 binding activity.
Participants were randomized to one of three dosing co-
horts and received active infusion or placebo weekly for
three weeks. Mean change from baseline in plasma HIV
RNA was in the range of −0.2 and −0.4 log copies/ml for
the two larger dose cohorts (8 mg/kg and 16 mg/kg) fol-
lowing the day 8 and day 15 infusions.
J. Victor Garcia took the strategy of targeting the
latent reservoir further by using an anti-Env antibody-
immunotoxin that delivered Pseudomonas exotoxin to
residual HIV infected cells in the humanized mouse
model [31]. Administering endotoxin every other day for
14 days to ART treated animals reduced cell-associated
HIV RNA production over ART alone. This approach
showed the susceptibility of the residual active HIV
reservoir to targeted cytotoxic therapy, and HIV–tar-
geted immunotoxins might compliment combination
chemotherapy.Ethics, regulatory issues and product development
Two roundtable panel sessions discussed key issues from
the diverse perspectives of the different stakeholders.
The first panel assembled HIV cure clinical trialists,
pharmaceutical industry representatives and community
ethicistsa to discuss issues that will accelerate product
development and regulatory agency approval for a rapid
and safe transition into the clinic of HIV cure therapies
having strong end-user acceptance and wide accessibility
for all patient populations. Open discussion with rele-
vant regulatory authorities was advised to clarify the
endpoints measured and the risk-benefit criteria re-
quired for an accelerated approval. Appropriate end-
points are especially important for combination cure
therapies, such as a small molecule inhibitor together
with a biologic and a vaccine. Although analytical treat-
ment interruption (ATI) was previously considered un-
acceptable, it is now a valid option for cure strategies in
appropriate well-controlled patient populations to min-
imise the potential risk of viral rebound. At these early
stages of clinical cure investigation, it is unlikely that re-
search of blood samples will be sufficient, and tissue
sampling will also be necessary, at least for a portion of
study participants, to gain insight into biomarkers for
long-term control.
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tient expectations provided a timely reminder of the
need to address the biomedical question of HIV cure in
parallel to the social and ethical questions. The panel-
listsb, who included scientists and clinicians involved in
cure research, community members, research funders
and bioethics specialists, resolved that the scientific ex-
citement for a potential HIV cure should not detract at-
tention from the financial, social, ethical and moral
implications of cure research. Many of the ethical con-
siderations for HIV cure research have been recently
reviewed [32] and it is clear that no standard set of eth-
ical rules can apply to the entire field of cure research.
As for many HIV research areas, research towards cure
should be carried out in concert with HIV patients. A
deeper and meaningful understanding of patient expec-
tations and willingness to participate in HIV cure studies
will be paramount to the success of the field.
Conclusion
The “Towards a Cure” symposium captured the increas-
ing research momentum based on the growing scientific
understanding of the HIV reservoir and the increasing
evidence from cases of HIV remission or cure. There is
increasing interest in chemotherapeutic interventions
promoting viral remission, and the first small steps have
been encouraging. Early data from clinical studies with
HDACi showed they were safe, well tolerated and suc-
cessfully stimulated unspliced HIV RNA as the primary
endpoint, providing optimism for broadly applicable
viral reactivation strategies. However, viral RNA has not
yet been linked with viral protein expression, and reduc-
tion in proviral load. Other biomarkers are needed that
better correlate with elimination of the viral reservoir
during curative interventions. Importantly, more HIV-
specific activating drugs are following and these offer
better specificity for HIV induction, and may potentially
team with therapeutic vaccines or other strategies to
eliminate cells containing reawakened HIV. But there is
clearly a long way to go and key challenges lie in the
search for combination interventions that not only lead
to activation of latent HIV infection, but also significant
decreases in the size of the HIV reservoir.
Evidence is mounting that early implementation of
ART can assist in achieving viral control off therapy,
possibly by preventing the seeding of virus into reser-
voirs that endure for the life of the patient. It remains to
be resolved if the reservoir seeded during chronic infec-
tion differs from that laid down in the primary infection,
and if it can be eliminated by chemotherapeutic
intervention.
There are still large gaps in our understanding of the
molecular mechanisms that restrict the expression and
release of replication competent HIV from the differenttissue reservoirs. While restrictive epigenetic and tran-
scriptional programs largely underpin the limited HIV
expression from most residual integrated proviruses, it is
clear that various other molecular mechanisms can
reversibly restrict viral expression, producing a diverse
reservoir of residual latent provirus. An increasingly im-
portant impediment in the field is access to validated
methods to measure the true size of the relevant replica-
tion competent latent virus reservoir.
The terms “sterilising” and “functional” cure have been
used to describe patients who have achieved complete
eradication or who control viral replication in the ab-
sence of ART, respectively [33]. Whereas the two con-
cepts are valid, the meaning of ‘functional’ is unclear
and - recognising the clear parallels with cancer thera-
peutics – the term “HIV remission without ART” has
been proposed. The precise definition ‘remission’ still
needs to be agreed, for example the duration of un-
detectable viraemia required or the risk of transmission.
HIV cure research has benefited from strong interac-
tions between basic scientists and clinicians, but it is
clear that important insights provided by social scientists
and members of the HIV community are required to de-
termine the expectations surrounding HIV cure and the
acceptability of different curative strategies. A trans-
disciplinary approach must include non-HIV experts to
bring new insights from the fields of oncology, other
chronic infections and inflammatory diseases. Wide con-
sultation is also needed to identify the appropriate con-
ditions for interruption of ART and the protocols for
monitoring viral recrudescence during treatment inter-
ruptions and the thresholds for reinstating therapy.Endnotes
aRoundtable panelists: David Margolis, University of
North Carolina at Chapel Hill (Chair); Guenter Kraus,
Tibotec/Janssen; Veronica Miller, The Forum for HIV
collaborative research; Bill Whittaker, National Associ-
ation of People living with HIV Australia; Hiroyu
Hatano, University of California San Francisco.
bJintanat Ananworanich, The Thai Red Cross AIDS
Research Centre (chair), Jeremy Sugarman (Johns
Hopkins Berman Institute of Bioethics, United States),
Laurindo Garcia (B-Change), Eric Fleutelot (Sidaction),
Bruno Spire (Inserm), Rowena Johnston (amfAR), Sha-
ron Lewin (Alfred Hospital, Monash University, Burnet
Institute).
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